International Clinical Trial: A Phase 1, Randomized, Double-blinded, Placebo-Controlled, Single and Multiple Oral Doses Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of TAK-279 in Healthy Chinese Subjects

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121697) titled 'A Phase 1, Randomized, Double-blinded, Placebo-Controlled, Single and Multiple Oral Doses Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of TAK-279 in Healthy Chinese Subjects' on April 1.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Huashan Hospital, Fudan University

Condition: None

Intervention: Cohort 1 (TAK-279 Group):TAK-279 30 mg, once daily (QD), oral Cohort 1 (Placebo Group):Placebo, once daily (QD), oral Cohort 2 (TAK-279 Group):TAK-279 60 mg, once daily (QD), oral

Recruitment Status: Not Recruiting

Phase: 1

Date of First Enrollment: 2024-06-24 ...